Clinical Study on Shaoyaozhitong Mixture in Treatment of Stage III-IV Endometriosis

In: Zhongguo zhongyiyao xinxi zazhi · 2014 · W2393452497
article OA: closed CC0
View on OpenAlex

Abstract

Objective To study the effect of Shaoyaozhitong Mixture on stage Ⅲ-Ⅳ endometriosis, and explore its mechanism. Methods Ninty-five cases of stage Ⅲ-Ⅳ endometriosis were randomly divided into three groups. The traditional Chinese medicine(TCM) group(31 cases) was treated with Shaoyaozhitong Mixture, the GnRHa group(31 cases) was treated with Triptorelin Acetate for Injection, while the expectant group(33 cases) received no medications. The changes of CA125, TNF-α and VEGF levels, visual pain score and SF-36 score, total effective rate, pregnancy and recurrence were compared. Results There were significant increases in CA125, TNF-α and VEGF levels, visual analogue pain score and SF-36 score in all the three groups after treatment(P 0.05). The decline of CA125, TNF-α and VEGF levels and visual analogue pain score in TCM group and GnRHa group was significantly faster and greater than that of the expectant group(P 0.05). The total effective rates of TCM group was 83.9%(26/31), GnRHa group was 87.1%(27/31), and expectant group was 60.6%(20/33), TCM group and GnRHa group were superior to the expectant group, respectively(P0.05). The pregnancy rate was higher and recurrence rate was lower in TCM group and GnRHa group than that of expectant group, but there was no statistical difference(P 0.05). Conclusion Shaoyaozhitong Mixture is effective in treating endometriosis by inhibiting the growth of ectopic endometrium.

My notes (saved in your browser only)

Condition tags

endometriosis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK